Zydus Lifesciences Ltd.

Foreign Investment Promotion Board (FIPB) has recommended Cadila Healthcare’s proposal for equity infusion of Rs 5000 crore to the Cabinet Committee on Economic Affairs (CCEA). The company is seeking approval for fresh equity infusion of up to Rs 5,000 crore under FDI route by QIBs through Qualified Institutional Placement on a private placement basis for the expansion of the business. Currently, the Finance Ministry can approve investments up to Rs 3,000 crore with amounts exceeding that having to be referred to the Cabinet panel.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.